Literature DB >> 7984409

Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene.

L C Harris1, J S Remack, T P Brent.   

Abstract

The DNA repair enzyme, O6-methylguanine DNA methyltransferase (MGMT) is responsible for repair of damage induced by alkylating agents that produce adducts at O6-guanine in DNA. Although the MGMT gene promoter has housekeeping gene promoter characteristics, unlike these genes which are expressed at a constant level, MGMT transcriptional activity varies between cell types. During an attempt to identify regions of the MGMT regulatory sequence sensitive to variations in transcription factors between cell types, we have identified a 59 bp enhancer which is required for efficient MGMT promoter function. This fragment produced increased transcriptional activity in reporter gene constructs containing either the MGMT or UMP-synthase promoter when transfected into either of two cell lines; it seems therefore that this enhancer may interact with relatively common trans-acting factors. Functional activity is only detected when the enhancer is in 'cis' with respect to the promoter, suggesting that complexes are formed between proteins bound to the enhancer and promoter sequences. We propose that the enhancer-binding protein may be a novel transcription factor since there are no obvious consensus sequences within the 59 bp sequence for known DNA-binding proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7984409      PMCID: PMC308508          DOI: 10.1093/nar/22.22.4614

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  42 in total

Review 1.  The molecular biology of nucleotide excision repair of DNA: recent progress.

Authors:  E C Friedberg
Journal:  J Cell Sci Suppl       Date:  1987

2.  Nuclear proteins from lactating mammary glands bind to the promoter of a milk protein gene.

Authors:  H Lubon; L Hennighausen
Journal:  Nucleic Acids Res       Date:  1987-03-11       Impact factor: 16.971

3.  Two nuclear factors compete for the skeletal muscle actin promoter.

Authors:  K Walsh; P Schimmel
Journal:  J Biol Chem       Date:  1987-07-15       Impact factor: 5.157

4.  CAT vectors for analysis of eukaryotic promoters and enhancers.

Authors:  E Prost; D D Moore
Journal:  Gene       Date:  1986       Impact factor: 3.688

Review 5.  Mechanisms of carcinogenesis induced by alkylating agents.

Authors:  R Saffhill; G P Margison; P J O'Connor
Journal:  Biochim Biophys Acta       Date:  1985-12-17

Review 6.  Transcriptional activation: a complex puzzle with few easy pieces.

Authors:  R Tjian; T Maniatis
Journal:  Cell       Date:  1994-04-08       Impact factor: 41.582

7.  Cell-type specific protein binding to the enhancer of simian virus 40 in nuclear extracts.

Authors:  I Davidson; C Fromental; P Augereau; A Wildeman; M Zenke; P Chambon
Journal:  Nature       Date:  1986 Oct 9-15       Impact factor: 49.962

8.  Topography of simian virus 40 A protein-DNA complexes: arrangement of pentanucleotide interaction sites at the origin of replication.

Authors:  A L DeLucia; B A Lewton; R Tjian; P Tegtmeyer
Journal:  J Virol       Date:  1983-04       Impact factor: 5.103

9.  Repair of alkylated DNA in Escherichia coli. Methyl group transfer from O6-methylguanine to a protein cysteine residue.

Authors:  M Olsson; T Lindahl
Journal:  J Biol Chem       Date:  1980-11-25       Impact factor: 5.157

10.  A simplified assay for O6-methylguanine-DNA methyltransferase activity and its application to human neoplastic and non-neoplastic tissues.

Authors:  B Myrnes; K Norstrand; K E Giercksky; C Sjunneskog; H Krokan
Journal:  Carcinogenesis       Date:  1984-08       Impact factor: 4.944

View more
  15 in total

1.  Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene.

Authors:  G S Watts; R O Pieper; J F Costello; Y M Peng; W S Dalton; B W Futscher
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

Authors:  Hinke F van Thuijl; Tali Mazor; Brett E Johnson; Shaun D Fouse; Koki Aihara; Chibo Hong; Annika Malmström; Martin Hallbeck; Jan J Heimans; Jenneke J Kloezeman; Marie Stenmark-Askmalm; Martine L M Lamfers; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchell S Berger; Peter Söderkvist; Barry S Taylor; Annette M Molinaro; Pieter Wesseling; Jaap C Reijneveld; Susan M Chang; Bauke Ylstra; Joseph F Costello
Journal:  Acta Neuropathol       Date:  2015-02-28       Impact factor: 17.088

3.  Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.

Authors:  H Pinson; G Hallaert; J Van der Meulen; F Dedeurwaerdere; D Vanhauwaert; C Van den Broecke; J Van Dorpe; D Van Roost; J P Kalala; T Boterberg
Journal:  J Neurooncol       Date:  2019-11-07       Impact factor: 4.130

4.  Prognosis of oligodendroglial tumor with ring enhancement showing central necrotic portion.

Authors:  Ki-Young Choi; Tae-Young Jung; Shin Jung; Young-Hee Kim; Kyung-Sub Moon; In-Young Kim; Sam-Suk Kang; Kyung-Hwa Lee
Journal:  J Neurooncol       Date:  2010-08-25       Impact factor: 4.130

5.  The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.

Authors:  Shuguang Leng; Amanda M Bernauer; Chibo Hong; Kieu C Do; Christin M Yingling; Kristina G Flores; Mathewos Tessema; Carmen S Tellez; Randall P Willink; Elizabeth A Burki; Maria A Picchi; Christine A Stidley; Michael D Prados; Joseph F Costello; Frank D Gilliland; Richard E Crowell; Steven A Belinsky
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

6.  Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.

Authors:  Shaun D Fouse; Jean L Nakamura; C David James; Susan Chang; Joseph F Costello
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

7.  MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks.

Authors:  Lichy Han; Maulik R Kamdar
Journal:  Pac Symp Biocomput       Date:  2018

8.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Authors:  Shadi Lalezari; Arthur P Chou; Anh Tran; Orestes E Solis; Negar Khanlou; Weidong Chen; Sichen Li; Jose A Carrillo; Reshmi Chowdhury; Julia Selfridge; Desiree E Sanchez; Ryan W Wilson; Mira Zurayk; Jonathan Lalezari; Jerry J Lou; Laurel Ormiston; Karen Ancheta; Robert Hanna; Paul Miller; David Piccioni; Benjamin M Ellingson; Colin Buchanan; Paul S Mischel; Phioanh L Nghiemphu; Richard Green; He-Jing Wang; Whitney B Pope; Linda M Liau; Robert M Elashoff; Timothy F Cloughesy; William H Yong; Albert Lai
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

9.  Aberrant MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors.

Authors:  Martin Hasselblatt; Jörg Mühlisch; Brigitte Wrede; Birgit Kallinger; Astrid Jeibmann; Ove Peters; Tezer Kutluk; Johannes E A Wolff; Werner Paulus; Michael C Frühwald
Journal:  J Neurooncol       Date:  2008-09-16       Impact factor: 4.130

10.  SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer.

Authors:  Joice Kuroiwa-Trzmielina; Fan Wang; Robert W Rapkins; Robyn L Ward; Daniel D Buchanan; Aung Ko Win; Mark Clendenning; Christophe Rosty; Melissa C Southey; Ingrid M Winship; John L Hopper; Mark A Jenkins; Jake Olivier; Nicholas J Hawkins; Megan P Hitchins
Journal:  Clin Cancer Res       Date:  2016-06-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.